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CD158k molecules belong to the family of killer cell immunoglobulin-like receptors (KIR) that are expressed on a
minor population of circulating NK and CD8þ T lymphocytes. Here, we report a strong positive correlation between
the percentage of CD158kþ blood lymphocytes analyzed by ﬂow cytometry and the percentage of atypical
circulating cells (Sezary cells) determined by cytomorphology in a large group of patients with Sezary syndrome.
Moreover, we show that circulating CD4þCD158kþ lymphocytes correspond to the malignant clonal cell
population. Our ﬁndings suggest that the CD158k marker could be a useful tool for the evaluation of the circulating
tumoral burden and the follow-up of patients with Sezary syndrome.
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Sezary syndrome (SS) is an erythrodermic form of cuta-
neous T cell lymphoma. One of the main criteria needed for
the diagnosis of SS is the presence of atypical mononuclear
cells (Sezary cells) in the blood (Vonderheid et al, 2002).
Until now, there has been no specific phenotypic marker for
Sezary cells.
CD158k/KIR3DL2 is an MHC class I antigen receptor that
belongs to the family of killer cell immunoglobulin-like
receptors (KIR) (Pende et al, 1996). In normal individuals, it
is expressed on a minor NK cell subset and on rare CD3þ
CD8þ circulating T lymphocytes (Moretta et al, 1997). In pre-
vious studies we found that fresh blood tumor CD4þ
lymphocytes of Sezary patients expressed the CD158k recep-
tor (Bagot et al, 2001; Musette et al, 2003). Further, in situ
analysis revealed that CD158k is expressed by cutaneous
tumor lymphocytes from SS patients, but not from patients
with early mycosis fungoides (Wechsler et al, 2003).
The aim of this report was to study the correlation
between the percentages of atypical circulating cells and
the percentages of lymphocytes expressing the CD158k
receptor from the blood of a large group of Sezary patients.
After informed consent and approval by ethics commit-
tee (CCPPRB; Hoˆpital Henri Mondor, Cre´teil), we analyzed
peripheral blood samples from 34 patients with SS before
treatment and in 12 of them during evolution (T1 and T2).
The diagnosis of SS relied on erythroderma, cutaneous
histology showing a specific infiltrate, a Sezary cell count of
more than 10% (mean: 49%; range: 10%–90%) of blood
lymphocytes, and a PCR-DGGE-detected identical T cell
clone (Theodorou et al, 1995) in the skin and blood. Controls
were peripheral blood samples from six erythrodermic
patients (three drug reactions, one atopic dermatitis, one
mycosis fungoides with no circulating Sezary cells, and one
pityriasis rubra pilaris) and ten normal individuals.
The Sezary cell count and the flow cytometry analysis
were performed at the same time. Sezary cell count was
carried out by cytomorphologic subjective cell-by-cell eye-
ball analysis. Peripheral blood mononuclear cells (PBMC)
were analyzed by flow cytometry with various monoclonal
antibodies (mAb), including anti-CD4, anti-CD26 and anti-
CD158k. The TCRVb repertoire was performed with a panel
of anti-TCRVb-specific mAb (Coulter-Beckman, Miami,
Florida), whereas the CDR3 size analysis of Vb2/Cb PCR
products and the TCRb-VDJ sequences were carried out as
previously described (Bagot et al, 1998). Statistical analysis
of the results was performed with GraphPad StatMate
software, using the Pearson correlation test.
As expected, the percentages of CD4þ cells from SS
patient PBMC (mean: 78%; range: 12%–98%) (Table I) were
increased compared with normal or erythrodermic patient
PBMC (35%–56%). The mean percentages of CD4þCD26
blood lymphocytes (59%) (Table I) were higher than in
normal individuals, where these lymphocyte populations
usually account for less than 30%. Further, in 14 patients,
with whom the analysis was performed, we found that the
percentages of Sezary cells were correlated to the percen-
tages of CD4þCD26 (p¼0.030), as previously reported
(Bernengo et al, 2001; Jones et al, 2001).
Next, we found that the percentages of CD158kþ
PBMC were higher in Sezary patients (mean: 27%; range:
0%–80%) (Table I) than in erythrodermic and normal
Abbreviations: KIR, killer cell immunoglobulin-like receptors; mAb,
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controls (mean: 6%; range: 5%–12%). Importantly, we
found a positive correlation between the percentages of
CD158kþ PBMC and the percentages of atypical circulat-
ing cells (r¼0.56, p¼ 0.0006). We also found a positive
correlation between the percentages of CD158kþCD4þ
PBMC and the percentages of atypical circulating
cells (r¼0.57, p¼ 0.0018) in 27 analyzed samples. The
correlation study on 46 samples from the 34 patients,
with 12 additional samples during evolution (two com-
plete remissions, four partial remissions, and six stable
disease), demonstrated an even higher correlation
(r¼0.60, po0.0001), suggesting a parallel evolution of the
percentages of atypical circulating cells and of CD158kþ
PBMC.
Table I. Cytomorphologic Sezary count and phenotypic analysis by ﬂow cytometry










1 17 80 21 54
2 37 98 10 93
3 54 96 79 82
4a 80 92 80 90
5 80 92 20 76
6 85 93 74 68
7 10 55 14 nd
8 14 74 0 nd
9 24 70 0 nd
10 58 88 40 nd
11 58 63 13 nd
12 66 74 5 nd
13a 53 90 70 nd
14 80 81 20 nd
15 89 98 65 nd
16a 90 87 40 nd
17 15 75 0 nd
18 16 68 11 nd
19a 21 84 18 nd
20 48 90 38 nd
21 52 12 12 nd
22 73 95 20 nd
T1 T2 T1 T2 T1 T2 T1 T2
23 17 15 70 70 0 0 40 nd
24 78 80 93 78 30 30 75 nd
25 33 3 58 65 19 0 19 nd
26 60 42 93 80 5 5 88 nd
27 59 49 68 70 15 23 49 nd
28 23 55 68 69 16 20 nd 44
29 65 56 89 85 80 70 nd 26
30 62 0 68 78 8 6 nd 22
31 24 19 65 62 19 13 nd nd
32 71 0 84 40 32 0 nd nd
33 58 29 95 75 40 30 nd nd
34 16 0 60 60 14 7 nd nd
aPatients with TCRVb PCR-analysis; T1, first sample; T2, second sample.
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Four of the 34 patients’ PBMC (12%) failed to react with
anti-CD158k mAb by flow cytometry, while the count of
atypical circulating cells reached 14%–24% of lymphocytes
(Table I). Interestingly, we demonstrated by RT-PCR the
presence of CD158k transcripts in one of these four patients
that we could test, whereas highly purified CD4þ blood
lymphocytes from healthy individuals lacked CD158k
transcript expression.
To demonstrate that circulating CD158kþ lymphocytes
corresponded to Sezary cells, we separated them by flow
cytometry and analyzed them for their TCR repertoire. In the
representative experiment shown in Fig 1 performed with
patient 4 exhibiting 80% Sezary cells, we demonstrated a
similar percentage of TCRVb2þ circulating lymphocytes by
flow cytometry. Interestingly, we found that 80% of cir-
culating lymphocytes were reactive with both anti-TCRVb2
and anti-CD158k mAb (Fig 1a). It must be noted that all
CD158kþ lymphocytes were included in the TCRVb2þ cell
population. Further, we separated the TCRVb2þCD158kþ
cell population in order to determine its clonality. Figure 1b
and c shows that the TCRVb2þ lymphocytes exhibit a
unique TCRVb junctional region, indicating that CD158k
receptor expression is associated to the malignant clonal
population. These results were obtained with three different
SS patients. These patients had respectively 53% (patient
13), 90% (patient 16), and 21% (patient 19) circulating
Sezary cells. The circulating lymphocytes were reactive
with both anti-TCRVb (respectively Vb22, Vb8, Vb11) and
anti-CD158k mAb. The CD158kþTCRVbþ populations
reached respectively 70%, 40%, and 20%.
In this study, we confirm that the loss of CD26 molecules
is a relevant negative marker of Sezary cells (Bernengo
et al, 2001, Jones et al, 2001). Interestingly, we found that
CD158kþ PBMC are markedly increased in Sezary
patients. For the first time, we found a positive correlation
between the percentages of CD158kþ PBMC and the
percentages of atypical circulating cells in a large group
of Sezary patients. Furthermore, we demonstrate that
the circulating CD158kþ T cell population constitutes a
homogenous dominant T cell clone. Thus, CD158k is the
only positive phenotypic marker available in SS and
represents a new useful tool for diagnosis, evaluation of
the circulating tumoral burden, and follow-up of patients
with SS. The next step will be to determine the prognostic
value of the CD158k molecule by a prospective study
performed on a larger group of patients.
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Figure 1
Expression of CD158kþ receptor by the malignant clonal population. (a) Double-immunofluorescence analysis of the expression of CD158k
and TCRVb2 molecules on circulating lymphocytes from a patient with 80% of Sezary cells, using fluorescein isothiocyanate (FITC) and
phycoerythrin (PE). (b) CDR3 size analysis of TCRVb2 transcripts in the CD158kþTCRVb2þ population isolated with a flow cytometer cell sorter. (c)
TCRVb2 chain junctional region sequence of the CD158kþTCRVb2þ sorted population.
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